Physician profile
Richard E Friedenheim
NPI 1144238676
$627,448.23
in general payments reported to CMS, 2019-2025
29 companies · $87K in 2025
The $87K reported for 2025 was more than what 99% of Pulmonary Disease providers received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $107K · 2020: $30K · 2021: $68K · 2022: $71K · 2023: $103K · 2024: $161K · 2025: $87K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $231K · Travel and Lodging: $44K · Honoraria: $33K · Consulting Fee: $29K · Food and Beverage: $11K · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $1,950 · Education: $209.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $231,393.80 |
| Travel and Lodging | $43,806.13 |
| Honoraria | $33,082.00 |
| Consulting Fee | $29,297.00 |
| Food and Beverage | $11,097.50 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $1,950.00 |
| Education | $208.75 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Jazz Pharmaceuticals INC. | $193,831.81 | 2019-2025 | |
| Genzyme Corporation | $193,063.06 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $121,002.21 | 2019-2025 | Dupixent |
| Axsome Therapeutics, INC. | $58,178.77 | 2023-2025 | Sunosi |
| Boehringer Ingelheim Pharmaceuticals, INC. | $16,846.57 | 2019-2020 | |
| Avadel Cns Pharmaceuticals, LLC | $15,450.81 | 2023-2025 | Lumryz |
| Glaxosmithkline, LLC. | $10,312.88 | 2019-2025 | Trelegy Ellipta, Arexvy, Nucala |
| Genentech USA, INC. | $9,524.26 | 2019-2023 | Xolair |
| Mylan Specialty L.P. | $5,085.91 | 2019-2024 | Yupelri |
| Sunovion Pharmaceuticals INC. | $1,927.67 | 2019 | |
| Harmony Biosciences LLC | $823.29 | 2020-2025 | Wakix |
| Inari Medical, INC. | $208.85 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $195.09 | 2019-2024 | Fasenra, Airsupra, Symbicort |
| Insmed, INC. | $138.48 | 2019-2025 | Brinsupri, Arikayce |
| United Therapeutics Corporation | $138.26 | 2019-2024 | Tyvaso |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Inspire Medical Systems, INC. | $133.05 | 2023-2025 | Inspire |
| Merck Sharp & Dohme LLC | $111.07 | 2022-2025 | Belsomra, Zerbaxa |
| Philips North America LLC | $109.12 | 2019-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $72.96 | 2019-2021 | |
| Amgen INC. | $68.24 | 2023-2024 | Tezspire |
| Resmed Corp | $55.02 | 2019-2023 | |
| Advanced Respiratory, INC | $33.71 | 2019 | |
| Alexion Pharmaceuticals, INC. | $29.77 | 2025 | Ultomiris |
| Sanofi-Aventis U.S. LLC | $29.00 | 2021 | |
| Actelion Pharmaceuticals US, INC. | $25.75 | 2019 | |
| Verona Pharma, INC. | $21.50 | 2025 | Ohtuvayre |
| Takeda Pharmaceuticals U.S.A., INC. | $20.29 | 2024 | Aralast |
| Circassia INC. | $10.83 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Richard Friedenheim listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.